KR20200134253A - 약제학적 병용물 - Google Patents

약제학적 병용물 Download PDF

Info

Publication number
KR20200134253A
KR20200134253A KR1020207029300A KR20207029300A KR20200134253A KR 20200134253 A KR20200134253 A KR 20200134253A KR 1020207029300 A KR1020207029300 A KR 1020207029300A KR 20207029300 A KR20207029300 A KR 20207029300A KR 20200134253 A KR20200134253 A KR 20200134253A
Authority
KR
South Korea
Prior art keywords
amino acid
seq
acid sequence
ser
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207029300A
Other languages
English (en)
Korean (ko)
Inventor
스테판 페레티
넬슨 귀레이로
엔사르 할리로빅
세바스티엔 제이
아스트리드 줄리온
진성 량
크리스토페 마일레
후이-친 왕
옌스 뷔르트너
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20200134253A publication Critical patent/KR20200134253A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020207029300A 2018-03-20 2019-03-18 약제학적 병용물 Ceased KR20200134253A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862645754P 2018-03-20 2018-03-20
US62/645,754 2018-03-20
PCT/IB2019/052166 WO2019180576A1 (en) 2018-03-20 2019-03-18 Pharmaceutical combinations

Publications (1)

Publication Number Publication Date
KR20200134253A true KR20200134253A (ko) 2020-12-01

Family

ID=66251830

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207029300A Ceased KR20200134253A (ko) 2018-03-20 2019-03-18 약제학적 병용물

Country Status (14)

Country Link
US (1) US20210363254A1 (https=)
EP (1) EP3768717A1 (https=)
JP (2) JP2021518348A (https=)
KR (1) KR20200134253A (https=)
CN (1) CN111868088A (https=)
AU (2) AU2019240200B2 (https=)
BR (1) BR112020018755A2 (https=)
CA (1) CA3092307A1 (https=)
CL (1) CL2020002379A1 (https=)
IL (1) IL277334A (https=)
MX (1) MX2020009614A (https=)
RU (1) RU2020133811A (https=)
TW (1) TWI791794B (https=)
WO (1) WO2019180576A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
ES2771926T3 (es) 2014-09-13 2020-07-07 Novartis Ag Terapias de combinación

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
US8815926B2 (en) 2012-01-26 2014-08-26 Novartis Ag Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
US20130245089A1 (en) 2012-03-19 2013-09-19 Hoffmann-La Roche Inc. Method for administration
SG10201900002QA (en) 2014-01-24 2019-02-27 Dana Farber Cancer Institue Inc Antibody molecules to pd-1 and uses thereof
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
WO2016100882A1 (en) * 2014-12-19 2016-06-23 Novartis Ag Combination therapies
US20180222982A1 (en) * 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
RU2020142739A (ru) * 2015-08-28 2021-01-15 Новартис Аг Ингибиторы mdm2 и их комбинации
GB201517217D0 (en) * 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
WO2017106656A1 (en) * 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
HK1254635A1 (zh) * 2015-12-17 2019-07-26 Novartis Ag C-met抑制剂与pd-1抗体分子的组合及其用途
EP4368200A3 (en) * 2017-04-05 2024-07-17 Boehringer Ingelheim International GmbH Anticancer combination therapy

Also Published As

Publication number Publication date
IL277334A (en) 2020-10-29
AU2019240200A1 (en) 2020-09-10
AU2019240200B2 (en) 2022-07-21
CA3092307A1 (en) 2019-09-26
CL2020002379A1 (es) 2021-03-05
CN111868088A (zh) 2020-10-30
AU2022209328A1 (en) 2022-10-20
TW201945001A (zh) 2019-12-01
TWI791794B (zh) 2023-02-11
JP2021518348A (ja) 2021-08-02
WO2019180576A1 (en) 2019-09-26
BR112020018755A2 (pt) 2021-01-05
RU2020133811A3 (https=) 2022-04-20
MX2020009614A (es) 2020-10-07
US20210363254A1 (en) 2021-11-25
JP2024012300A (ja) 2024-01-30
RU2020133811A (ru) 2022-04-20
EP3768717A1 (en) 2021-01-27

Similar Documents

Publication Publication Date Title
KR102114562B1 (ko) 암의 치료에 사용하기 위한 5-브로모-2,6-디-(1h-피라졸-1-일)피리미딘-4-아민
EP3344658B1 (en) Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
KR20190017767A (ko) C-raf 억제제의 치료적 용도
KR102357621B1 (ko) Pd-1에 대한 항체 분자 및 그의 용도
JP6840127B2 (ja) がんの治療における抗ｐｄ−１抗体および抗ｍ−ｃｓｆ抗体の併用
IL296673A (en) Anti-ccr8 antibodies for cancer treatment
JP2021522801A (ja) ヒトネクチン４に特異的な抗体
CN112262155A (zh) 结合cd39的抗体及其用途
KR20180030911A (ko) Pd-1 길항제와 egfr 억제제의 조합물
KR20180133399A (ko) 인간 폴리오바이러스 수용체(ｐｖｒ)에 특이적인 항체
KR20180088907A (ko) Pd-1에 대한 항체 분자 및 그의 용도
US20230042258A1 (en) Anti-il-27 antibodies and uses thereof
EP3625260A1 (en) Treatment of cancer with anti-gitr agonist antibodies
KR20210117277A (ko) 인간 넥틴-2에 특이적인 항체
EP3894440A1 (en) Anti-il-27 antibodies and uses thereof
JP2024012300A (ja) 医薬併用
KR20220066346A (ko) 항-il-27 항체 및 이의 용도
KR20220062056A (ko) Pd-1 축 억제제 및 항-페리오스틴 항체의 사용에 의한 암 치료 방법
KR20230159823A (ko) Cd112r에 대한 항체 및 이의 용도
KR102226100B1 (ko) 암의 치료에 사용하기 위한 5-브로모-2,6-디-(1h-피라졸-1-일)피리미딘-4-아민

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20201013

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220317

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240831

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20241107

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D